Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut

NCT00171873 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

85

Enrollment

OTHER

Sponsor class

Conditions

Neuroendocrine Tumors

Interventions

DRUG: Octreotide LAR (Long-acting release)
DRUG: Placebo

Sponsor

Carmen Schade-Brittinger